Clinical Study
Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid
Table 1
Patient characteristics prior to study entry.
| | All patients () | BMD group () |
| | Baseline | | | | Median age (yrs) at HSCT (range) | 43.8 (18–64) | 43.9 (18–64) | | Gender (male/female) | 24/12 | 18/8 | | Underlying disease | | | | AML | 15 | 11 | | CML | 11 | 8 | | ALL | 5 | 4 | | NHL | 3 | 1 | | MDS | 2 | 2 |
| | Allo-HSCT | | | | Type of HSCT (BM/PBSCT/both) | 16/16/4 | 12/10/4 | | HLA (identical/different) | 28/8 | 19/7 | | Donor (related/unrelated) | 19/17 | 15/11 | | Donor sex (male/female) | 18/18 | 12/14 | | Cytoreduction prior to conditioning | 11 | 9 | | TBI (/4–8 Gy/10–12 Gy) | 9/12/15 | 7/9/10 | | Busulphan | 9 | 7 | | Cyclophosphamide | 35 | 26 | | ATG | 32 | 23 | | Immunosuppression | | | | CSA-MTX | 24 | 18 | | CSA-MMF | 12 | 8 |
| | Post-allo-HSCT | | | | Acute/chronic GvHD | 28/26 | 20/17 | | Corticosteroids prior to study | 29 | 20 | | Duration (days) ± SD | 152 ± 173 | 159 ± 198 | | Cumulative dose (g) ± SD | 11.1 ± 8.6 | 11.1 ± 9.1 | | Corticosteroids during the study | 29 | 20 | | Duration (days) ± SD | 628 ± 209 | 625 ± 121 | | Cumulative dose (g) ± SD | 5.4 ± 2.4 | 5.2 ± 1.6 |
|
|
